Share of Voice for Biotech & Pharma

What share of voice means for Biotech & Pharma

The MLR bottleneck is the defining pain. Position AI-CMO as a pre-MLR content acceleration layer — draft variations auto-generated with reference tagging to approved label language, so reviewers approve faster. Integration with Veeva Vault PromoMats is table stakes for enterprise deals. Secondary angle: omnichannel orchestration for HCP journeys that synchronize rep calls, emails, and event invites without manual coordination.

For Biotech & Pharma teams the relevant marketing pains are: Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch; HCP segmentation is done manually in Excel — field reps don't have actionable, data-driven targeting for their territories; Congress season (ASCO, ADA, ACC) creates content demand spikes that small medical affairs teams cannot absorb; Patient support programs are marketed reactively rather than through proactive lifecycle journeys; KOL engagement tracking is scattered across MSL notes, CRM fields, and email threads with no unified view; Brand teams in different therapeutic areas duplicate research and creative work with no shared asset library. FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute

SOV Across Channels

Paid SOV is measured by comparing your ad impressions or spend against total category spend — tools like Google Ads' Impression Share report provide this directly for search. Organic SOV tracks the share of non-branded keyword rankings your domain holds versus competitors. Social SOV measures branded mention volume relative to competitor mention volume.

Each channel's SOV is a distinct signal. A brand can have dominant paid SOV but minimal organic SOV if they rely on media budget rather than content authority. Long-term, organic and earned SOV are more defensible because they do not disappear when budgets are cut.

Running share of voice for Biotech & Pharma with CoMo

CoMo's agents apply share of voice across HCP email, med-ed portals, LinkedIn, congresses/events, speaker programs, rep-triggered digital, patient advocacy partnerships for Biotech & Pharma companies — tuned to VP Commercial Marketing at mid-size pharma; Director of Marketing Excellence at specialty biotech; Head of Omnichannel at large pharma and run under your approval, alongside every other marketing function.

RELATED